01 August 2018
Visiongain’ has launched a new pharma report Global Transnational Regenerative Medicine Market: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.
Regenerative medicine has been undergoing a period of sustained innovation over the last two decades. Tissue engineering and stem cell research in particular have seen a level of interest which it hasn’t received for a long while. Novel cell sources such as induced pluripotent stem cells have also helped to open new areas of research which had previously seemed impossible due to limited resources. There are potential opportunities in the market for participating companies, however certain risks and limitations also abound. The global regulations surrounding regenerative medicine remains fragmented. The changes to regulatory processes in the leading national and regional markets should help to drive progress in the regenerative medicine market.
The lead analyst of the report commented “Growth in the global translational regenerative medicine market will be fuelled particularly by stem cell therapies and tissue engineering advancements, as well as the emergence of commercial gene therapy products. The improvements in regulation of stem cell research on a regional level will increase its attractiveness. We note that advancements such as 3D bioprinting should enable the development of tissues which can be used for toxicology testing purposes.
Furthermore, strong government support for regenerative medicine particularly in countries such as China and South Korea, as well as the accelerated regulatory pathway for regenerative medicine in Japan will drive the growth in stem cell therapies.”
Leading companies featured in the report include Alphatec Spine, Anterogen, Athersys, Avita Medical, AxoGen, Medipost, Mesoblast, NuVasive, Ocata Therapeutics, Organogenesis, Pharmicell, Regenerys, TiGenix, UniQure, Vericel Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth